Alk reports positive results with its tablet vaccine against tree pollen allergy in a phase 3 study involving 952 children aged 5 to 17 years in Canada and Europe.

The vaccine was tested for the treatment of allergic rhinoconjunctivitis caused by tree pollen and the study met its primary endpoint, confirming its potential.

ALK writes in an announcement on Wednesday.

ALK’s Executive Vice President of Research and Development, Henriette Mersebach, welcomes the results and says that the company has now successfully completed the clinical development of all five of ALK’s tablet vaccines against respiratory allergy in children.

”The study results are consistent with previous results from studies with tablets and clearly confirm the benefits of treating respiratory allergy with our tablet vaccines from early childhood.”

”The study’s positive result is also important for ALK’s long-term growth ambitions and our ability to transform the medical treatment of children with allergies,” she said in the announcement.

The tree pollen allergy tablet is marketed in Europe as Itulazax and in Canada as Itulatek.

ALK will now initiate a dialog with the relevant authorities about the expansion of the current product indications.

”Subject to approval, the tree pollen allergy tablet could be available for younger patients in Europe and Canada in 2025. ALK expects to present further details from the study at a scientific congress in 2024,” the company writes.

(Translated using DeepL with additional editing by Mads Oddershede)